SEARCH

SEARCH BY CITATION

References

  • 1
    Penn I, Hammond W, Brettschneider L, Starzl TE. Malignant lymphomas in transplantation patients. Transplant Proc 1969; 1: 106112.
  • 2
    Nourse JP, Jones K, Gandhi MK. Epstein–Barr virus-related post-transplant lymphoproliferative disorders: Pathogenetic insights for targeted therapy. Am J Transplant 2011; 11: 888895.
  • 3
    Crespo-Leiro MG, Alonso-Pulpón L, Vázquez de Prada JA, et al. Malignancy after heart transplantation: Incidence, prognosis and risk factors. Am J Transplant 2008; 8: 10311039.
  • 4
    Trappe R, Oertel S, Leblond V, et al. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): The prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol 2012; 13: 196206.
  • 5
    Starzl TE, Nalesnik MA, Porter KA, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984; 1: 583587.
  • 6
    Hopwood P, Crawford DH. The role of EBV in post-transplant malignancies: A review. J Clin Pathol 2000; 53: 248254.
  • 7
    Stevens SJ, Verschuuren EA, Pronk I, et al. Frequent monitoring of Epstein–Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood 2001; 97: 11651171.
  • 8
    van Esser JW, van der Holt B, Meijer E, et al. Epstein–Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. Blood 2001; 98: 972978.
  • 9
    Wagner HJ, Cheng YC, Huls MH, et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood 2004; 103: 39793981.
  • 10
    Wagner HJ, Fischer L, Jabs WJ, Holbe M, Pethig K, Bucsky P. Longitudinal analysis of Epstein–Barr viral load in plasma and peripheral blood mononuclear cells of transplanted patients by real-time polymerase chain reaction. Transplantation 2002; 74: 656664.
  • 11
    Lee TC, Savoldo B, Rooney CM, et al. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. Am J Transplant 2005; 5: 22222228.
  • 12
    Bakker NA, Verschuuren EA, Erasmus ME, et al. Epstein–Barr virus-DNA load monitoring late after lung transplantation: A surrogate marker of the degree of immunosuppression and a safe guide to reduce immunosuppression. Transplantation 2007; 83: 433438.
  • 13
    Funch DP, Walker AM, Schneider G, Ziyadeh NJ, Pescovitz MD. Ganciclovir and aciclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients. Am J Transplant 2005; 5: 28942900.
  • 14
    Malouf MA, Chhajed PN, Hopkins P, Plit ML, Glanville A. Antiviral prophylaxis prevents lymphoprofilerative disease in lung transplant recipients. J Heart Lung Transplant 2001; 20: 200.
  • 15
    Roche. MabThera summary of product characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000165/WC500025821.pdf. Accessed July 3, 2013.
  • 16
    van Esser JW, Niesters HG, van der Holt B, et al. Prevention of Epstein–Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 2002; 99: 43644369.
  • 17
    Savoldo B, Huls MH, Liu Z, et al. Autologous Epstein–Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection. Blood 2002; 100: 40594066.
  • 18
    Brengel-Pesce K, Morand P, Schmuck A, et al. Routine use of real-time quantitative PCR for laboratory diagnosis of Epstein–Barr virus infections. J Med Virol 2002; 66: 360369.
  • 19
    Fafi-Kremer S, Brengel-Pesce K, Barguès G, et al. Assessment of automated DNA extraction coupled with real-time PCR for measuring Epstein–Barr virus load in whole blood, peripheral mononuclear cells and plasma. J Clin Virol 2004; 30: 157164.
  • 20
    Deback C, Fillet AM, Dhedin N, et al. Monitoring of human cytomegalovirus infection in immunosuppressed patients using real-time PCR on whole blood. J Clin Virol 2007; 40: 173179.
  • 21
    Fafi-Kremer S, Morand P, Barranger C, et al. Evaluation of the Epstein–Barr virus R-gene quantification kit in whole blood with different extraction methods and PCR platforms. J Mol Diagn 2008; 10: 7884.
  • 22
    Stewart S, Winters GL, Fishbein MC, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 2005; 24: 17101720.
  • 23
    Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon, France: IACR Press, 2008.
  • 24
    Engels EA, Pfeiffer RM, Fraumeni JF Jr, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA 2011; 306: 18911901.
  • 25
    Choquet S, Trappe R, Leblond V, Jäger U, Davi F, Oertel S. CHOP-21 for the treatment of post-transplant lymphoproliferative disorders (PTLD) following solid organ transplantation. Haematologica 2007; 92: 273274.
  • 26
    Choquet S, Leblond V, Herbrecht R, et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: Results of a prospective multicenter phase 2 study. Blood 2006; 107: 30533057.
  • 27
    Oertel SH, Verschuuren E, Reinke P, et al. Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant 2005; 5: 29012906.
  • 28
    González-Barca E, Domingo-Domenech E, Capote FJ, et al. Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease. Haematologica 2007; 92: 14891494.
  • 29
    Choquet S, Oertel S, Leblond V, et al. Rituximab in the management of the post-transplantation lymphoproliferative disorder after solid organ transplantation: Proceed with caution. Ann Hematol 2007; 92: 273274.
  • 30
    Haque T, Wilkie GM, Jones MM, et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: Results of a phase 2 multicenter clinical trial. Blood 2007; 110: 11231131.
  • 31
    Mañez R, Breinig MC, Linden P, et al. Posttransplant lymphoproliferative disease in primary Epstein–Barr virus infection after liver transplantation: The role of cytomegalovirus disease. J Infect Dis 1997; 176: 14621467.
  • 32
    Smith JM, Corey L, Healey PJ, Davis CL, McDonald RA. Adolescents are more likely to develop posttransplant lymphoproliferative disorder after primary Epstein–Barr virus infection than younger renal transplant recipients. Transplantation 2007; 83: 14231428.
  • 33
    Curtis RE, Travis LB, Rowlings PA, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: A multi-institutional study. Blood 1999; 94: 22082216.
  • 34
    Cherikh WS, Kauffman HM, McBride MA, Maghirang J, Swinnen LJ, Hanto DW. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation 2003; 76: 12891293.
  • 35
    Opelz G, Daniel V, Naujokat C, Fickenscher H, Döhler B. Effect of cytomegalovirus prophylaxis with immunoglobulin or with antiviral drugs on post-transplant non-Hodgkin lymphoma: A multicentre retrospective analysis. Lancet Oncol 2007; 8: 212218.
  • 36
    McDiarmid SV, Jordan S, Kim GS, et al. Prevention and preemptive therapy of posttransplant lymphoproliferative disease in pediatric liver recipients. Transplantation 1998; 66: 16041611.
  • 37
    Rooney CM, Smith CA, Ng CY, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein–Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998; 92: 15491555.
  • 38
    Baldanti F, Grossi P, Furione M, et al. High levels of Epstein–Barr virus DNA in blood of solid-organ transplant recipients and their value in predicting posttransplant lymphoproliferative disorders. J Clin Microbiol 2000; 38: 613619.
  • 39
    Gustafsson A, Levitsky V, Zou JZ, et al. Epstein–Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: Prophylactic infusion of EBV-specific cytotoxic T cells. Blood 2000; 95: 807814.
  • 40
    Comoli P, Labirio M, Basso S, et al. Infusion of autologous Epstein–Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood 2002; 99: 25922598.
  • 41
    Humar A, Hébert D, Davies HD, et al. A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein–Barr virus related posttransplant lymphoproliferative disorder. Transplantation 2006; 81: 856861.
  • 42
    Green M, Michaels MG, Katz BZ, et al. CMV-IVIG for prevention of Epstein–Barr virus disease and posttransplant lymphoproliferative disease in pediatric liver transplant recipients. Am J Transplant 2006; 6: 19061912.
  • 43
    Savoldo B, Goss JA, Hammer MM, et al. Treatment of solid organ transplant recipients with autologous Epstein–Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood 2006; 108: 29422949.
  • 44
    Worth A, Conyers R, Cohen J, et al. Pre-emptive rituximab based on viraemia and T cell reconstitution: A highly effective strategy for the prevention of Epstein–Barr virus-associated lymphoproliferative disease following stem cell transplantation. Br J Haematol 2011; 155: 377385.
  • 45
    Fryer JF, Heath AB, Wilkinson DE, et al. Collaborative study to evaluate the proposed 1st WHO international standard for Epstein–Barr virus (EBV) for nucleic acid amplification technology (NAT)-based assays. Geneva, Switzerland: WHO, 2011. WHO/BS/2011.2172.